Eligibility criteria in phase 3 randomized controlled trials in gastric cancer
Gastric Cancer · 2025
DOI: 10.1007/s10120-025-01653-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastric Cancer, 2025. Verfasst von Katarzyna Marcisz-Grzanka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology and Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology (MSCNRIO), Wawelska 15, 02-034, Wars…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Clinical Trials, Phase III as Topic, Randomized Controlled Trials as Topic, Patient Selection. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The purpose of this study was to examine the eligibility criteria in phase 3 randomized controlled trials (RCTs) in gastric cancer.
Methods
The analysis included 207 RCTs of systemic treatments, started between 2009 and 2024, and registered at the WHO International Clinical Trials Registry Platform (ICTRP).
Results
93 (44.9%) trials had an upper age limit of 85 years of age or lower (coprimary outcome). In multivariable analysis, these limits were less likely in RCTs with the sites located in North America (adjusted odds ratio [aOR], 0.06; 95% confidence interval [CI] 0.01–0.26; p < 0.001). Only 3 (1.4%) trials were specifically dedicated to older patients. 138 (66.7%) trials excluded patients with Eastern Cooperative Oncology Group (ECOG) score > 1 (coprimary outcome); these criteria were more likely in more recent trials (aOR, 4.49; 95% CI 2.11–9.94; p < 0.001). However, the odds of excluding individuals with ECOG score > 1 were not significantly associated with any type of the investigational treatment including chemotherapy ( p > 0.05). Moreover, many trials excluded patients with brain metastases ( n = 91; 44%) and those with comorbidities, most frequently liver disorders ( n = 170; 82.1%). None of the RCTs excluded patients based on frailty.
Conclusions
The eligibility criteria in phase 3 RCTs in gastric cancer are fairly strict. Recommendations presented in this article will allow the investigators to improve the enrollment of some clinically relevant populations of patients, especially older persons, individuals with inadequate performance status, and those with comorbidities, without substantially compromising the safety of trials participants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Oncology and Radiotherapy, Maria Sklodowska-Curie National Research Institute of Oncology (MSCNRIO), Wawelska 15, 02-034, Warsaw, Poland.
- Department of Clinical Immunology, Medical University of Warsaw, Nowogrodzka 59, 02-006, Warsaw, Poland.
- Institute of Human Biology and Evolution, Faculty of Biology, Adam Mickiewicz University, Uniwersytetu Poznanskiego 6, 61-614, Poznan, Poland.
- Department of Clinical Immunology, Medical University of Warsaw, Nowogrodzka 59, 02-006, Warsaw, Poland. jan.borysowski@wum.edu.pl.
ORCID-Profile: Jan Borysowski
Zitieren
APA
Marcisz-Grzanka, K., Kłosowska, D., Harhala, M., & Borysowski, J. (2025). Eligibility criteria in phase 3 randomized controlled trials in gastric cancer. Gastric Cancer. https://doi.org/10.1007/s10120-025-01653-3
Vancouver
Marcisz-Grzanka K, Kłosowska D, Harhala M, Borysowski J. Eligibility criteria in phase 3 randomized controlled trials in gastric cancer. Gastric Cancer. 2025. doi:10.1007/s10120-025-01653-3
BibTeX
@article{MarciszGrzanka2025,
author = {Marcisz-Grzanka, Katarzyna and Kłosowska, Danuta and Harhala, Marek and Borysowski, Jan},
title = {Eligibility criteria in phase 3 randomized controlled trials in gastric cancer},
journal = {Gastric Cancer},
year = {2025},
doi = {10.1007/s10120-025-01653-3}
}
EUVIMED